Literature DB >> 22482451

Huntington disease and the huntingtin protein.

Zhiqiang Zheng1, Marc I Diamond.   

Abstract

Huntington disease (HD) is a devastating neurodegenerative disease that derives from CAG repeat expansion in the huntingtin gene. The clinical syndrome consists of progressive personality changes, movement disorder, and dementia and can develop in children and adults. The huntingtin protein is required for human development and normal brain function. It is subject to posttranslational modification, and some events, such as phosphorylation, can play an enormous role in regulating toxicity of the huntingtin protein. The function of huntingtin in the cell is unknown, and it may play a role as a scaffold. Multiple mouse models of HD have now been created with fragments and full-length protein. The models show variable fidelity to the disease in terms of genetics, pathology, and rates of progression. Pathogenesis of HD involves cleavage of the protein and is associated with neuronal accumulation of aggregated forms. The potential mechanisms of neurodegeneration are myriad, including primary effects of protein homeostasis, gene expression, and mitochondrial dysfunction. Specific therapeutic approaches are similarly varied and include efforts to reduce huntingtin gene expression, protein accumulation, and protein aggregation.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22482451     DOI: 10.1016/B978-0-12-385883-2.00010-2

Source DB:  PubMed          Journal:  Prog Mol Biol Transl Sci        ISSN: 1877-1173            Impact factor:   3.622


  35 in total

Review 1.  Translational potential of astrocytes in brain disorders.

Authors:  Alexei Verkhratsky; Luca Steardo; Vladimir Parpura; Vedrana Montana
Journal:  Prog Neurobiol       Date:  2015-09-16       Impact factor: 11.685

2.  Loss of caveolin-1 expression in knock-in mouse model of Huntington's disease suppresses pathophysiology in vivo.

Authors:  Eugenia Trushina; Christie A Canaria; Do-Yup Lee; Cynthia T McMurray
Journal:  Hum Mol Genet       Date:  2013-09-10       Impact factor: 6.150

Review 3.  Proteostasis in Huntington's disease: disease mechanisms and therapeutic opportunities.

Authors:  Rachel J Harding; Yu-Feng Tong
Journal:  Acta Pharmacol Sin       Date:  2018-04-05       Impact factor: 6.150

4.  Huntington's disease: lessons from prion disorders.

Authors:  Melanie Alpaugh; Francesca Cicchetti
Journal:  J Neurol       Date:  2021-02-24       Impact factor: 4.849

5.  Hip2 ubiquitin-conjugating enzyme has a role in UV-induced G1/S arrest and re-entry.

Authors:  Nan Hee Hong; Yeong Jin Tak; Hyangshuk Rhim; Seongman Kang
Journal:  Genes Genomics       Date:  2018-09-27       Impact factor: 1.839

Review 6.  Metabolic disturbances in diseases with neurological involvement.

Authors:  João M N Duarte; Patrícia F Schuck; Gary L Wenk; Gustavo C Ferreira
Journal:  Aging Dis       Date:  2013-11-30       Impact factor: 6.745

7.  Probing the Huntingtin 1-17 membrane anchor on a phospholipid bilayer by using all-atom simulations.

Authors:  Sébastien Côté; Vincent Binette; Evgeniy S Salnikov; Burkhard Bechinger; Normand Mousseau
Journal:  Biophys J       Date:  2015-03-10       Impact factor: 4.033

8.  Postnatal and adult consequences of loss of huntingtin during development: Implications for Huntington's disease.

Authors:  Eduardo E Arteaga-Bracho; Maria Gulinello; Michael L Winchester; Nandini Pichamoorthy; Jenna R Petronglo; Alicia D Zambrano; Julio Inocencio; Chirstopher D De Jesus; Joseph O Louie; Solen Gokhan; Mark F Mehler; Aldrin E Molero
Journal:  Neurobiol Dis       Date:  2016-09-10       Impact factor: 5.996

9.  Free-Energy Landscape of the Amino-Terminal Fragment of Huntingtin in Aqueous Solution.

Authors:  Vincent Binette; Sébastien Côté; Normand Mousseau
Journal:  Biophys J       Date:  2016-03-08       Impact factor: 4.033

Review 10.  Mitochondrial dynamics in neurodegeneration.

Authors:  Kie Itoh; Ken Nakamura; Miho Iijima; Hiromi Sesaki
Journal:  Trends Cell Biol       Date:  2012-11-16       Impact factor: 20.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.